Externally-Led Patient-Focused
Drug Development Meeting
July 22, 2022 │10:00 AM – 3:00 PM EDT
What is an Externally-Led Patient-Focused Drug Development meeting?
Externally-led Patient Focused Drug (EL-PFDD) meetings give the Food and Drug Administration (FDA) and other key stakeholders — including medical product developers, health care providers, and federal partners — an important opportunity to hear directly from patients, their families, caregivers, and patient advocates about the symptoms that matter most to them, the impact the disease has on patients’ daily lives, and patients’ experiences with currently available treatments. This input can inform FDA’s decisions and oversight both during drug development and during their review of a marketing application for a new drug.
Click here to learn more about Externally-Led Patient-Focused Drug Development meetings.
Who was involved in the EL-PFDD?
James Valentine, JD, MHS
Co-Moderator
Kathleen O’Sullivan-Fortin
Co-Moderator
Florian Eichler, MD
Associate Professor of Neurology at Harvard Medical School
Larry Bauer, RN, MA
Regulatory Advisor
Thank you to our partner organizations!
Thank you to our sponsors!
